
Knowledge of risk predictors of incident heart failure (HF) in patients with type‐2 diabetes (T2D) is crucial given the frequent coexistence of the two conditions and the fact that T2D doubles the risk of incident HF. The present position paper, derived from an expert panel workshop organised by the Heart Failure Association of the European Society of Cardiology, summarises the current knowledge and gaps in evidence regarding the use of a series of different biomarkers, reflecting various pathogenic pathways for the prediction of incident HF and CV events in patients with T2D and those with established HF and T2D.
Like
Save
Share